BioArctic AB's (publ) partner Eisai will present the efficacy, safety and biomarker results from the Phase 3 confirmatory Clarity AD clinical trial for lecanemab (development code: BAN2401), at the 15th Clinical Trials on Alzheimer's Disease (CTAD) conference, held in San Francisco, CA and virtually from November 29 to December 2. Additionally, BioArctic will present a poster on Aß protofibrils and binding properties of lecanemab and Eisai will present other important research from the lecanemab clinical development program in several oral and poster presentations. Topline results from Clarity AD were announced in late September and showed that lecanemab met the primary endpoint and all key secondary endpoints with highly statistically significant results, and the profile of Amyloid-Related Imaging Abnormalities (ARIA) incidence was within expectations. Key lecanemab CTAD presentations; Clarity AD: Results from the Phase 3 confirmatory Clarity AD clinical trial of lecanemab in patients with early AD will be presented in a scientific session on November 29 at 4:50 p.m. PT.

Eisai will host a live webcast of presentations in the session and can be viewed live on the investors section of the Eisai Co. Ltd. website. Aß protofibrils and lecanemab ninding properties: Research studying the characterization of Aß protofibrils and the unique binding properties and mechanisms of Aß clearance of lecanemab (Poster #P029).

AHEAD 3-45 Study: An evaluation of tau PET screening data from the Phase 3 AHEAD 3-45 study of lecanemab for associations with plasma p-tau217 and cognitive testing (Late Breaker Oral #LB1). A study exploring increased accuracy of amyloid PET prediction in preclinical AD using plasma levels for Aß42/40 and p-tau217 ratios from screening data from the Phase 3 study AHEAD 3-45 (Late Breaker Oral #LB2).